[1] FDA. US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. December 2009. Available at: https://www.fda.gov/media/77832/download. Accessed: November 7, 2019.
[2] Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA. 1995;273(1):59-65.
[3] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424.
[4] Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014 Oct;23(5):489-502.
[5] Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20(11):1771-85.
[6] Nguyen J, Popovic M, Chow E, Cella D, Beaumont JL, Chu D, et al. EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review. J Comp Eff Res. 2015 Mar;4(2):157-66.
[7] Deshpande P, Chittkathopottamal AN, Bommareddy LS, Mallasamy S. Development and validation of a patient-reported questionnaire to assess the quality of life outcomes of Indian breast cancer patients. Value Health. 2012;15(4):A236.
[8] Vanlemmens L, Congard A, Antoine P, Fournier E, Lesur A, Loustalot C, et al. Construction of two quality of life questionnaires from young breast cancer patients and their partner. Cancer Res. 2013;73(24).
[9] Vanlemmens L, Fournier E, Christophe V, Boinon D, Toudic-Emily F, Duffour B, et al. The impact of breast cancer on the quality of life of young women and their partners depending on the treatment in the period concerned. Psycho-Oncology. 2009;18:S149.
[10] Zhang Z, Zhang X, Wei L, Lin Y, Wu D, Xie S, et al. Questionnaire to assess quality of life in patients with breast cancer – Validation of the Chinese version of the EORTC QLQ-BR 53. Breast. 2017;32:87-92.
[11] El Fakir S, Abda N, Bendahhou K, Zidouh A, Bennani M, Errihani H, et al. The European Organization for Research and Treatment of Cancer quality of life questionnaire-BR23 Breast Cancer-Specific Quality of Life Questionnaire: psychometric properties in a Moroccan sample of breast cancer patients. BMC Res Notes. 2014 Jan 21;7:53.
[12] Alawadhi SA, Ohaeri JU. Validity and reliability of the European Organization for Research and Treatment in Cancer Quality of Life Questionnaire (EORTC QLQ): experience from Kuwait using a sample of women with breast cancer. Ann Saudi Med. 2010 Sep-Oct;30(5):390-6.
[13] Bener A, Alsulaiman R, Doodson L, El Ayoubi HR. An assessment of reliability and validity of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 among breast cancer patients in Qatar. J Family Med Prim Care. 2017 Oct-Dec;6(4):824-31.
[14] Tan ML, Idris DB, Teo LW, Loh SY, Seow GC, Chia YY, et al. Validation of EORTC QLQ-C30 and QLQ-BR23 questionnaires in the measurement of quality of life of breast cancer patients in Singapore. Asia Pac J Oncol Nurs. 2014 Apr-Jun;1(1):22-32.
[15] Cerezo O, Onate-Ocana LF, Arrieta-Joffe P, Gonzalez-Lara F, Garcia-Pasquel MJ, Bargallo-Rocha E, et al. Validation of the Mexican-Spanish version of the EORTC QLQ-C30 and BR23 questionnaires to assess health-related quality of life in Mexican women with breast cancer. Eur J Cancer Care (Engl). 2012 Sep;21(5):684-91.
[16] Michels FA, Latorre Mdo R, Maciel Mdo S. Validity, reliability and understanding of the EORTC-C30 and EORTC-BR23, quality of life questionnaires specific for breast cancer. Rev Bras Epidemiol. 2013 Jun;16(2):352-63.
[17] Shuleta-Qehaja S, Sterjev Z, Shuturkova L. Evaluation of reliability and validity of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30, Albanian version) among breast cancer patients from Kosovo. Patient Prefer Adherence. 2015;9:459-65.
[18] Simons WR. Content validity of signs and symptoms measures with the EORTC core module in women with locally advanced or metastatic breast cancer (MBC): a phase II trial with eribulin mesylate. J Clin Oncol. 2013;31(15_suppl):e17576-e.
[19] Snyder CF, Blackford AL, Okuyama T, Akechi T, Yamashita H, Toyama T, et al. Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician's attention. Qual Life Res. 2013 Dec;22(10):2685-91.
[20] Wallwiener M, Simoes E, Hartkopf AD, Taran FA, Keilmann L, Sickenberger N, et al. Reliability and acceptance of e-based survey instruments for measuring patient reported outcomes (PRO) in breast cancer patients: First results of the ePROCOM study. Cancer Res. 2017;77(4).
[21] Keilmann L, Matthies L, Simoes E, Hartkopf AD, Sokolov AN, Walter CB, et al. Quality of life measurement in breast cancer patients: Reliability of an ePRO tool using EORTC QLQ-C30. Eur J Obstet Gynecol Reprod Biol. 2019;234:e148-e9.
[22] Wallwiener M, Matthies L, Simoes E, Keilmann L, Hartkopf AD, Sokolov AN, et al. Reliability of an e-PRO tool of EORTC QLQ-C30 for measurement of health-related quality of life in patients with breast cancer: Prospective randomized trial. J Med Internet Res. 2017 Sep 14;19(9):e322.
[23] Matthies LM, Taran FA, Keilmann L, Schneeweiss A, Simoes E, Hartkopf AD, et al. An electronic patient-reported outcome tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) questionnaire for measuring the health-related quality of life in patients with breast cancer: reliability study. J Med Internet Res. 2019 Jan 22;21(1):e10004.
[24] Bjelic-Radisic V, Bottomley A, Cardoso F, Cameron D, Brain E, Kuljanic K, et al. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23) - EORTC QLQ-BR45. Ann Oncol. 2018;29:viii59-viii60.
[25] Algamdi MM, Hanneman SK. Reliability estimates for the Arabic versions of the Cancer Behavior Inventory-Brief and the Functional Assessment of Cancer Therapy-Breast. J Nurs Meas. 2016 Dec 1;24(3):388-98.
[26] Patoo M, Allahyari AA, Moradi AR, Payandeh M. Persian version of Functional Assessment of Cancer Therapy- Breast (FACT-B) Scale: confirmatory factor analysis and psychometric properties. Asian Pac J Cancer Prev. 2015;16(9):3799-803.
[27] Jarkovský J, Skřivanová K, Benešová K, Nedvěd J, Brančíková D, Peterková H, et al. Validation of the Czech version of the FACT-B scale for measuring quality of life in breast cancer patients. Klinicka Onkologie. 2016;29:2S62.
[28] Kobeissi L, Saad MA, Doumit M, Mohsen R, Salem Z, Tfayli A. Face validity of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FACT- B) into formal Arabic. Middle East J Cancer. 2014;5(3):151-65.
[29] Ng R, Lee CF, Wong NS, Luo N, Yap YS, Lo SK, et al. Measurement properties of the English and Chinese versions of the Functional Assessment of Cancer Therapy-Breast (FACT-B) in Asian breast cancer patients. Breast Cancer Res Treat. 2012 Jan;131(2):619-25.
[30] Lee CF, Luo N, Ng R, Wong NS, Yap YS, Lo SK, et al. Comparison of the measurement properties between a short and generic instrument, the 5-level EuroQoL Group's 5-dimension (EQ-5D-5L) questionnaire, and a longer and disease-specific instrument, the Functional Assessment of Cancer Therapy-Breast (FACT-B), in Asian breast cancer patients. Qual Life Res. 2013 Sep;22(7):1745-51.
[31] Cheung YB, Lee CF, Luo N, Ng R, Wong NS, Yap YS, et al. Comparison of the measurement properties between the 5-level euroqol group's 5-dimension (EQ-5D-5l) questionnaire and the functional assessment of cancer therapy-breast (FACT-B) in Asian breast cancer patients. Value Health. 2012;15(7):A605.
[32] Lee CF, Ng R, Wong NS, Luo N, Yap YS, Lo SK, et al. Measurement properties of the eight-item abbreviated functional assessment of cancer therapy--breast symptom index and comparison with its 37-item parent measure. J Pain Symptom Manage. 2013 Apr;45(4):782-91.
[33] Garcia SF, Rosenbloom SK, Beaumont JL, Merkel D, Von Roenn JH, Rao D, et al. Priority symptoms in advanced breast cancer: development and initial validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16). Value Health. 2012 Jan;15(1):183-90.
[34] Krohe M, Tang DH, Klooster B, Revicki D, Galipeau N, Cella D. Content validity of the National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy - Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients. Health Qual Life Outcomes. 2019 May 29;17(1):92.
[35] Christophe V, Duprez C, Congard A, Antoine P, Lesur A, Fournier E, et al. The subjective experience of young women with non-metastatic breast cancer: the Young Women with Breast Cancer Inventory. Health Qual Life Outcomes. 2015 Jun 3;13:73.
[36] Horigan JL, Gralla RJ, Davis BJ, Hollen PJ, Petersen JA, Burg K, et al. Determining issues of importance for patients with breast cancer: Results of a web-based study in 1,072 patients to enhance the content validity for the development of a new health-related quality of life (QL) instrument, the Breast Cancer Symptom Scale (BCSS). J Clin Oncol. 2009;27(15):e20615.
[37] Harley C, Takeuchi E, Taylor S, Keding A, Absolom K, Brown J, et al. A mixed methods approach to adapting health-related quality of life measures for use in routine oncology clinical practice. Qual Life Res. 2012 Apr;21(3):389-403.
[38] Blazeby J, Sprangers M, Cull A, Groenvold M, Bottomley A. Guidelines for developing questionnaire modules: EORTC quality of life group. EORTC 2002.
[39] Wan C, Yang Z, Tang X, Zou T, Chen D, Zhang D, et al. Development and validation of the system of quality of life instruments for cancer patients: breast cancer (QLICP-BR). Support Care Cancer. 2009 Apr;17(4):359-66.
[40] Saptaningsih AB, Setiawan D, Rivany R, Aryandono T, Atthobari J, Dwiprahasto I. The Development of Quality of Life Questionnaire for Indonesian Breast Cancer Patients: INA-BCHRQoL. Asian Pac J Cancer Prev. 2018 May 26;19(5):1269-75.
[41] Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, et al. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann Oncol. 2020 Feb;31(2):283-8.